Affiliations · 75% USAL, CSIC, FICUS – 20% Other affiliations
Note · Master's students, undergraduate trainees, and visiting scientists are not included.
Report Section
A visual overview of CIC’s staff, research structure, publications, funding, technology transfer, education and outreach activity during 2024-2025.
- 0StaffAcross the institute
- 0Research groupsIn 2 programs
- 0Publications2024–2025
- 0.00M€Competitive fundingTotal awarded
- 0%Q1 publicationsTop-quartile journals
- 0Research linesAcross both programs
- 0Commercial agreementsWith industry
- 0Patent applicationsFiled in the period
Staff
People at CIC
A workforce of researchers, technicians and support staff across the institute.
Staff by gender
Distribution of CIC staff by gender.
Staff by gender: 227 women (68%) and 107 men (32%), out of 334 total staff.
- Women227 · 68%
- Men107 · 32%
Show data table
| Gender | Count | Share |
|---|---|---|
| Women | 227 | 68% |
| Men | 107 | 32% |
| Total | 334 | 100% |
Staff by role and gender
Headcount for each role, split by gender. Bar length is the role total.
Staff across 11 roles, split by gender. Totals: 133 men and 280 women. The largest groups are Technical Support Personnel and Ph.D. Researchers.
- Men
- Women
Show data table
| Role | Men | Women | Total |
|---|---|---|---|
| R4 Lab Chiefs | 15 | 8 | 23 |
| R3B Junior Group Leader | 3 | 0 | 3 |
| R3A Accredited Researchers | 2 | 1 | 3 |
| Senior Researchers | 12 | 10 | 22 |
| Postdoctoral Researchers | 12 | 34 | 46 |
| Ph.D. Researchers | 27 | 58 | 85 |
| Lab Technicians | 8 | 39 | 47 |
| Master Students | 11 | 27 | 38 |
| Undergrad Students | 8 | 14 | 22 |
| Visiting Scientists | 7 | 12 | 19 |
| Technical Support Personnel | 28 | 77 | 105 |
| Total | 133 | 280 | 413 |
Research Programs & Groups
Research overview
CIC's research is organized into programs, structured by research line, with groups nested under their line.
- 2
- Programs
- 11
- Research lines
- 28
- Research groups
Research lines
- Early signaling processes intrinsic to the tumor cell
- Mechanotransduction
- Characterization of signaling pathways involved in tumor-stroma interaction
- Regulation of chromosome segregation and dynamics
- Cancer epitranscriptomics
- Understanding, treatment, and diagnosis of hematological tumors
- Breast tumors
- Hepatobiliary tumors
- Hereditary cancer
- Bioinformatics and artificial intelligence
- Mechanisms of therapy resistance
Publications
Scientific output
In 2024-2025, CIC delivered advances in cancer biology, precision medicine, genome stability, and translational research, spanning breast, lung, liver, pancreatic, oral, and biliary cancers.
- 0Publications2024–2025
- 0CitationsAccumulated
- 0Q1 publications74% of total
- 0%Open accessOf all publications
Publications by year
Total publications per year, with the share in first-quartile (Q1) journals highlighted.
Publications: 184 in 2024 (130 in Q1 journals, 71%); 210 in 2025 (160 in Q1 journals, 76%). Total 394 publications, 290 in Q1 (74%).
- Q1 journals
- Other journals
Show data table
| Year | Total | Q1 | Q1 % | Citations | Open access % |
|---|---|---|---|---|---|
| 2024 | 184 | 130 | 71% | 2,255 | 83% |
| 2025 | 210 | 160 | 76% | 1,025 | 78% |
| Total | 394 | 290 | 74% | 3,280 | 80% |
Featured themes
Representative research themes from the period. Full detail lives in Featured Publications.
Competitive Funding
Funding
Competitive funding awarded to CIC researchers, broken down by scope, managing entity, type and status.
- 0.00M€Competitive fundingTotal awarded
- 0Funded projectsInternational, national & regional
- 0%Managed at CICOf total funding
Funding by scope
Competitive funding awarded by geographic scope, in millions of euros.
Competitive funding by scope: International 4.592 M€ across 14 projects; National 24.833 M€ across 80 projects; Regional 2.047 M€ across 12 projects.
Show data table
| Scope | Projects | Amount |
|---|---|---|
| International | 14 | 4.592 M€ |
| National | 80 | 24.833 M€ |
| Regional | 12 | 2.047 M€ |
Funding by managing entity
Which institution manages each share of the funding. 70% is managed at CIC.
Competitive funding by managing entity: FICUS 33% (10.40 M€); IBSAL 30.1% (9.48 M€); CSIC 27.3% (8.60 M€); USAL 9.5% (2.98 M€); Others 0.1% (0.02 M€). Total 31.48 M€.
- FICUS33% · 10.40 M€
- IBSAL30.1% · 9.48 M€
- CSIC27.3% · 8.60 M€
- USAL9.5% · 2.98 M€
- Others0.1% · 0.02 M€
Show data table
| Managing entity | Amount | Share |
|---|---|---|
| FICUS | €10,401,242 | 33% |
| IBSAL | €9,481,870 | 30.1% |
| CSIC | €8,596,389 | 27.3% |
| USAL | €2,984,648 | 9.5% |
| Others | €18,630 | 0.1% |
| Total | €31,482,779 | 100% |
Funding by type and status
Number of competitive projects by funding type, split into obtained and ongoing. Bar length is the project count.
Competitive funding projects by type: Private national: 18 projects (10 obtained, 8 ongoing); Private international: 6 projects (3 obtained, 3 ongoing); Public national: 63 projects (34 obtained, 29 ongoing); Public regional: 13 projects (9 obtained, 4 ongoing); Public international: 8 projects (3 obtained, 5 ongoing).
- Obtained
- Ongoing
Show data table
| Type | Obtained | Ongoing | Total | Amount |
|---|---|---|---|---|
| Private national | 10 | 8 | 18 | €6,901,493 |
| Private international | 3 | 3 | 6 | €3,456,712 |
| Public national | 34 | 29 | 63 | €17,932,308 |
| Public regional | 9 | 4 | 13 | €2,056,940 |
| Public international | 3 | 5 | 8 | €1,135,326 |
Industry & Technology Transfer
Technology transfer
Translating research into impact through industry agreements, private investment and intellectual property.
- 0Commercial agreementsWith industry partners
- 0.000M€Private investmentFrom collaborations
- 0Patent applicationsFiled in the period
Industry partners
Companies CIC collaborated with during the period.
- Boehringer Ingelheim
- BridgeBio Oncology Therapeutics
- Theras Inc.
- Blueprint Medicines Corporation
- Immunostep
Patent applications
3 applications filed in the reporting period.
Trimethoxystyryl derivatives for paclitaxel-resistant cancer
- EP24382305
- PCT/EP2025/057648
In vitro method for the identification of human Mesenchymal Stem/Stromal Cells
- EP21383041
- EP4433069A1
Patent application filed in collaboration with CancerAppy S.L.
- EP25382595.4
Education
Training & education
Doctoral and master's training, scientific seminars and professional development programs.
- 0PhD theses40 cancer biology · 3 biomedicine
- 0International mentionsOf PhD theses
- 0Master's thesesCompleted in the period
- 0Scientific seminarsHosted at CIC
Seminar speakers by origin
Origin of speakers across 77 scientific seminars.
Across 77 scientific seminars, speakers were 27% international (21), 33% national (25), 40% internal (31).
- International21 · 27%
- National25 · 33%
- Internal31 · 40%
Show data table
| Origin | Speakers | Share |
|---|---|---|
| International | 21 | 27% |
| National | 25 | 33% |
| Internal | 31 | 40% |
| Total | 77 | 100% |
Professional development
Non-academic training and additional programs offered to CIC researchers.
Non-academic training
- Core skills for your PhD: Communication, Time and Project Management
- Career Development for Scientists: From Introspection to Application
- Leadership workshop
- Managing Myself and Working with My Team: A Skills Upgrade for Group Leaders
- Scientific Writing: Putting Why Before How
- Oral Presentation: Beyond Slides
- Career Orientation: Alternatives to the Academic Career Path
Additional programs
- CIC Mentoring Program
- Research placement at the CIC awarded to the winner of the Biology Olympiad
- BioPhysal: First Salamanca International Advanced Biophysics and Structural Biology Course
- First and Second Euroflow Summer School
- Advanced courses of cytometry and clinical proteomics
Communication & Outreach
Communication & outreach
Bringing CIC's science to the public through media, events and social channels.
- 0Press releasesIssued in the period
- 0Scientific eventsOrganized
- 0Public engagementActivities
- 0Talks by womenBy female researchers
- 0VisitsHosted at CIC
- ~0Students hostedAcross visits
Media presence
- National radio programmes
- 3
- Full-page press features
- 2
- TV & press interviews
- 5+
- Prime-time TV reports
- 2
Social followers
Provisional · as of 3/06- X (Twitter)
- 4,698
- 8,331
Follower counts are provisional and pending a final update before publication.